Biotechnology

FluoGuide A/S Publishes Interim Report for the Period January - March 2024

May 30, 2024 3:05 AM

KØBENHAVN, DK / ACCESSWIRE / May 30, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 30 May 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2024. The Q1 report is available as an attached document to this press release and on FluoGuide's website. FluoGuide had no revenue for the period and posted a net loss of DKK 7,521 thousand (DKK 9,535 thousand) for the period 1 January...

Read more

DiviTum(R) TKa Results to be Presented at ASCO the World’s Largest Cancer Conference

May 30, 2024 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / May 30, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that results with DiviTum® TKa from the Spanish GEICAM/2014-12 FLIPPER trial will be presented at the world's largest cancer conference, the annual ASCO meeting on June 2, 2024 9:00 AM - 12:00 PM CDT. The data supports the use of DiviTum TKa to predict outcome and progression on first...

Read more

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

May 29, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces the successful completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate OTC access of STENDRA® (avanafil) for consumers. This important development follows the Company's recent execution of an AI...

Read more

Tharimmune to Present at 2024 BIO International Convention

May 29, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego. The Company will be presenting at the convention and will hold 1x1 meetings with investors...

Read more

Indica Labs Announces AI-Powered HALO(R) Software Release for Digital Pathology Research in Life Sciences

May 29, 2024 8:00 AM

Indica Labs, the global leader in AI-powered digital pathology solutions, announced today the release of the transformative new version of its industry leading life sciences software. The 4.0 versions of HALO®, HALO AI, and HALO Link offer researchers and pathologists unparalleled ease of use and performance, with even more opportunities to leverage advanced AI-powered image analysis in an open digital pathology ecosystem. The proliferation...

Read more

New Study Quantifies the Impact of Improved Clinical Trial Design Using Faro Health's Study Designer Tool

May 29, 2024 7:00 AM

Digital tool gives real-time feedback on the impact of changes to clinical study protocols, helping clinical teams reduce the cost, duration and burden of studies on sponsors, sites and patients. SAN DIEGO, CA / ACCESSWIRE / May 29, 2024 / A new study, published in the peer-reviewed journal Therapeutic Innovation & Regulatory Science and conducted in collaboration with Merck, shows that when Faro's Study Designer Tool was applied to clinical...

Read more

RNAConnect Launches UltraMarathonRT(TM), an Ultra-Processive Next-Generation Reverse Transcriptase

May 28, 2024 9:00 AM

BRANFORD, CT / ACCESSWIRE / May 28, 2024 / RNAConnect, a pioneering life science tools company, officially announced the commercial launch of UltraMarathonRT™ (uMRT), a next-generation, ultra-processive reverse transcriptase. Available as part of a Reverse Transcriptase Kit and a Template Switching Kit, uMRT is a highly engineered RT that overcomes the limitations of existing reverse transcriptases by creating full-length cDNAs from any RNA...

Read more

Ensysce Biosciences Regains Compliance with Nasdaq

May 28, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice on May 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the...

Read more

Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab

May 28, 2024 8:00 AM

LungOI Is Among The First AI-based Tests To Receive a Medicare Payment Rate. MIAMI, FL / ACCESSWIRE / May 28, 2024 / Imagene, a pioneer in AI-based precision oncology, is pleased to announce the culmination of key milestones in the commercialization of its AI-based NSCLC Biomarker Profiling Test, LungOITM. Earlier this year, Imagene secured a novel payment code and payment rate from the Centers for Medicare and Medicaid Services (CMS). LungOI -...

Read more

Ondine Biomedical Inc Announces Notice of Results, Investor Presentation, and AGM

May 28, 2024 2:00 AM

Ondine Biomedical Inc. (AIM:OBI) announces that it will publish its audited results for the year ended 31 December 2023 ("Full Year Results") and Annual Report 2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 10 June 2024, 16:30 BST (08:30 Pacific time). The presentation is open to all existing and...

Read more

FluoGuide Selects Laser System for Photothermal Cancer Therapy with FG001

May 27, 2024 4:00 AM

FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, has chosen laser system for the development of photothermal therapy (PTT). FluoGuide's lead product, FG001 fluoresces and is designed to bind urokinase-type plasminogen activator receptor (uPAR) making it specific to cancer and with a potential for most patients with solid cancer. Clinical data...

Read more

BioInvent to Host Virtual KOL Event on June 18, 2024, to Discuss BioInvent's Lead Candidates BI-1808 and BI-1206

May 24, 2024 9:15 AM

LUND, SWEDEN / ACCESSWIRE / May 24, 2024 / BioInvent International (STO:BINV) TNFR2 and FcyRIIB are promising targets in immuno-oncology. BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM...

Read more

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 24, 2024 9:00 AM

ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (Nasdaq:ASPI) and Calidi Biotherapeutics Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: ASP Isotopes:...

Read more

Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

May 23, 2024 5:15 PM

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDAC The encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confirmatory Phase 3 trial Biomarker analysis demonstrates correlation of mitazalimab-induced immune activation with clinical outcomes...

Read more

MMJ to Summons DEA Heads - Milgram DEA Director Removed from Marijuana Rescheduling Issue

May 23, 2024 3:15 PM

During a recent congressional hearing, Anne Milgram , Director of the Drug Enforcement Administration (DEA), passionately addressed the alarming surge in illegal fentanyl-related deaths . Her plea for action against this epidemic resonated widely. However, amidst this urgency, a significant contradiction emerges- the DEA's hindrance of marijuana research and drug development. DEA vs. Marijuana Research: A Troubling Double Standard Despite...

Read more

RNAConnect, Inc. Formally Launches Today to Drive RNA Analysis With Innovative Research Tools

May 23, 2024 9:00 AM

BRANFORD, CO / ACCESSWIRE / May 23, 2024 / RNAConnect, a pioneering life science reagent company, officially launches today, promising groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure. RNAConnect RNAConnect full-color horizontal company logo RNAConnect was founded by innovators in the RNA community, for innovators in the RNA community. It is anchored by the belief that better enzymatic tools for...

Read more

Longwood Healthcare Leaders Spring MIT to Convene Life Science Thought Leaders at MIT Koch Institute

May 23, 2024 7:45 AM

BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood Healthcare Leaders Spring MIT forum, co-hosted by Koch Institute Professors Phil Sharp and Bob Langer and held at MIT's Koch Institute, June 17-18, 2024. LHL.Logo The industry-leading meeting focuses on a broad spectrum of topics affecting the...

Read more

Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

May 23, 2024 7:00 AM

LUXEMBOURG / ACCESSWIRE / May 23, 2024 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Third Quarter Fiscal Year 2024 on Thursday, May 30, 2024, before the market opens. Moolec Logo Moolec Science Logo Moolec's Chief Executive Officer Gastón Paladini, Chief...

Read more

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

May 22, 2024 5:00 PM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024. "I am a strong believer in the potential of our innovative immune-oncology technologies...

Read more

InDevR Introduces Latest Solution for Influenza Vaccine Manufacturers, OmniFlu HA, to Simplify Vaccine Testing and Speed Time to Market

May 22, 2024 3:30 PM

Validated, off-the-shelf kit for multiplexed seasonal hemagglutinin (HA) detection and quantification addresses the unique challenges faced by vaccine developers and manufacturers. BOULDER, CO / ACCESSWIRE / May 22, 2024 / InDevR, Inc., a global leader in vaccine testing and multiplexed assay development for vaccine manufacturers, is excited to announce the launch of OmniFlu HA, a validated, off-the-shelf kit for seasonal influenza vaccine...

Read more